太龙药业
(600222)
| 流通市值：26.79亿 | | | 总市值：27.49亿 |
| 流通股本：5.59亿 | | | 总股本：5.74亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,069,908,736.55 | 1,442,869,622.59 | 993,909,739.6 | 560,317,916.01 |
| 营业收入 | 2,069,908,736.55 | 1,442,869,622.59 | 993,909,739.6 | 560,317,916.01 |
| 二、营业总成本 | 2,035,858,489.19 | 1,474,043,456.35 | 1,036,057,414.64 | 558,034,043.53 |
| 营业成本 | 1,505,186,410.23 | 1,077,930,515.79 | 750,241,722.52 | 406,839,571.39 |
| 税金及附加 | 9,925,630.41 | 6,310,362 | 4,569,296.93 | 2,440,919.54 |
| 销售费用 | 197,855,644.31 | 144,230,730.62 | 99,791,558.32 | 78,642,380.54 |
| 管理费用 | 141,643,215.57 | 104,037,111.62 | 75,756,745.95 | 33,243,147.85 |
| 研发费用 | 127,714,364.35 | 102,021,293.07 | 79,750,330.93 | 24,187,244.98 |
| 财务费用 | 53,533,224.32 | 39,513,443.25 | 25,947,759.99 | 12,680,779.23 |
| 其中:利息费用 | 51,796,995.6 | 38,313,070.04 | 24,657,612.82 | 12,122,545.06 |
| 其中:利息收入 | 2,168,525.16 | 1,702,819.49 | 1,134,797.98 | 164,517.36 |
| 加:公允价值变动收益 | -534,035.44 | 592,888.81 | -819,339.39 | -968,000 |
| 加:投资收益 | -5,889,831.01 | -3,983,798.68 | -2,487,060.68 | -1,738,337.26 |
| 资产处置收益 | 615,485.96 | 444,613.6 | 577,412.44 | 123,939.32 |
| 资产减值损失(新) | -2,462,115.49 | -4,783,812.76 | -4,414,940 | -472,319.49 |
| 信用减值损失(新) | -436,451.22 | 10,375,655.06 | -2,450,122.03 | 2,296,026.59 |
| 其他收益 | 18,823,220.79 | 7,787,997.08 | 3,482,074.23 | 1,290,881.98 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 44,166,520.95 | -20,740,290.65 | -48,259,650.47 | 2,816,063.62 |
| 加:营业外收入 | 8,565.16 | 8,564.26 | 527.5 | - |
| 减:营业外支出 | 1,212,619.75 | 258,333.35 | 130,728.03 | 3,594.96 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 42,962,466.36 | -20,990,059.74 | -48,389,851 | 2,812,468.66 |
| 减:所得税费用 | -1,866,821.32 | -1,469,383.79 | -5,549,936.9 | -475,911.79 |
| 六、净利润 | 44,829,287.68 | -19,520,675.95 | -42,839,914.1 | 3,288,380.45 |
| 持续经营净利润 | 44,829,287.68 | -19,520,675.95 | -42,839,914.1 | 3,288,380.45 |
| 归属于母公司股东的净利润 | 43,556,724.78 | -16,926,351.76 | -38,331,796.75 | 3,682,566.68 |
| 少数股东损益 | 1,272,562.9 | -2,594,324.19 | -4,508,117.35 | -394,186.23 |
| (一)基本每股收益 | 0.08 | -0.03 | -0.07 | 0.01 |
| (二)稀释每股收益 | 0.08 | -0.03 | -0.07 | 0.01 |
| 八、其他综合收益 | 6,587,224.43 | -60,524,667.89 | -71,207,757.23 | -29,619,370.55 |
| 归属于母公司股东的其他综合收益 | 6,587,224.43 | -60,524,667.89 | -71,207,757.23 | -29,619,370.55 |
| 九、综合收益总额 | 51,416,512.11 | -80,045,343.84 | -114,047,671.33 | -26,330,990.1 |
| 归属于母公司股东的综合收益总额 | 50,143,949.21 | -77,451,019.65 | -109,539,553.98 | -25,936,803.87 |
| 归属于少数股东的综合收益总额 | 1,272,562.9 | -2,594,324.19 | -4,508,117.35 | -394,186.23 |
| 公告日期 | 2024-03-28 | 2023-10-27 | 2023-08-19 | 2023-04-29 |
| 审计意见(境内) | 标准无保留意见 | | | |